Previous close | 20.72 |
Open | 20.71 |
Bid | 20.72 x N/A |
Ask | 20.99 x N/A |
Day's range | 20.71 - 20.90 |
52-week range | 15.24 - 20.90 |
Volume | |
Avg. volume | 1,470 |
Market cap | 85.791B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 16.44 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.70 (3.39%) |
Ex-dividend date | 16 May 2024 |
1y target est | N/A |
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see GSK plc...
(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t Track‘Seriously Underwater’ Home Mortgages Tick Up Across th
Starting out in the stock market can be confusing. Here, this Fool explains his strategy and picks out two shares he'd consider buying. The post New to the stock market? Here are 2 of the best shares to consider buying appeared first on The Motley Fool UK.